- Home
- NA vs ATYR Comparison
NA vs ATYR Comparison
Compare NA & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NA | ATYR |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.5M | 79.2M |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NA | ATYR |
|---|---|---|
| Price | $3.11 | $0.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 149.1K | ★ 2.0M |
| Earning Date | 08-15-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,369,693.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.75 | $0.64 |
| 52 Week High | $31.48 | $7.29 |
Technical Indicators
Market Signals| Indicator | NA | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 43.88 |
| Support Level | $2.98 | $0.70 |
| Resistance Level | $3.46 | $0.76 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 26.32 | 36.80 |
Price Performance
Historical ComparisonAbout NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.